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18F-FBB PET is a neuroimaging modality that is been increasingly used to assess
brain amyloid deposits in potential patients with Alzheimer’s disease (AD). In this work,
we analyze the usefulness of these data to distinguish between AD and non-AD
patients. A dataset with 18F-FBB PET brain images from 94 subjects diagnosed with
AD and other disorders was evaluated by means of multiple analyses based on t-test,
ANOVA, Fisher Discriminant Analysis and Support Vector Machine (SVM) classification.
In addition, we propose to calculate amyloid standardized uptake values (SUVs) using
only gray-matter voxels, which can be estimated using Computed Tomography (CT)
images. This approach allows assessing potential brain amyloid deposits along with the
gray matter loss and takes advantage of the structural information provided by most of
the scanners used for PET examination, which allow simultaneous PET and CT data
acquisition. The results obtained in this work suggest that SUVs calculated according to
the proposed method allow AD and non-AD subjects to be more accurately differentiated
than using SUVs calculated with standard approaches.
Keywords: quantitative analysis, multivariate analysis, florbetaben, Alzheimer’s disease, support vector machine,
positron emission tomography
1. INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting more than 5
million people in the United States (Alzheimer’s Association, 2018) and its prevalence in Europe
was estimated at 5.05% (Niu et al., 2017). In addition, the number of AD patients is expected
to increase during next decades because of the grow of the older population. Fortunately, the
development of new drugs has greatly improved the patient’s quality of life, especially when the
disease is detected at an early stage. Thus, an early and accurate diagnosis of AD is crucial.
The diagnosis of AD is usually supported by neuroimaging data of different modalities. During
the last decade, many research studies have demonstrated that both, structural and molecular
imaging, can be successfully used to evaluate patients with AD, including early stages and
prodromal AD (Johnson et al., 2012). Structural neuroimaging data such as magnetic resonance
imaging (MRI) or computed tomography (CT) allow us to estimate the global cerebral volume,
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which was found to significantly correlate with the rate of change
in mini-mental state examination scores, evidencing clinical
relevance to this marker in the disease progression (Frisoni et al.,
2010; Khedher et al., 2015). In addition, MRI and CT data can
be used to exclude treatable or reversible causes of dementia
(normal-pressure hydrocephalus, subdural hematoma, tumors,
etc.).
On the other hand, molecular neuroimages have been
widely used in differential diagnosis of dementia. For example,
Single Photon Emission Computer Tomography (SPECT) or
Positron Emission Tomography (PET) have been demonstrated
as valuable tools not only to separate AD patients and controls
(Segovia et al., 2010; Rathore et al., 2017) but also to monitor
the progression of AD (Hanyu et al., 2010). Probably, the most
common molecular neuroimaging modality for AD diagnosis is
the well-known 18F-Fludeoxyglucose (FDG) PET. These images
allow us to analyze the glucose brain metabolism and that way
to estimate the neurodegeneration of certain regions of the brain
(Illán et al., 2011; Perani et al., 2014; Cabral et al., 2015).
Conversely to 18F-FDG PET, amyloid imaging focuses on
the amyloid beta deposits that characterize AD. During last
years, several radiotracers have been proposed to examine these
AD hallmarks. The N-methyl-[11C]2-(4′-methylaminophenyl)-
6-hydroxybenzothiazole, more commonly referred to as
Pittsburgh Compound B (PIB), is an amyloid focused radiotracer
traditionally used for this purpose (Klunk et al., 2004). This drug
is a radioactive analog of thioflavin T, which binds to amyloid
plaques with high affinity, however, its reduced half-life (only
20 min) greatly limits its application (Klunk and Mathis, 2008).
Recently, new 18F-labeled tracers with similar efficacy to PIB and
longer half-life have been FDA approved: 18F-florbetapir in 2012,
18F-flutemetamol in 2013 and 18F-florbetaben (FBB) in 2014.
The validity of these radiotracers is supported by recent studies
(Landau et al., 2014; Rice and Bisdas, 2017) that emphasize the
added value of these radiotracers in discriminating between AD
and non-AD patients (Ceccaldi et al., 2018).
In this work, we analyze 18F-FBB PET data from AD and
non-AD patients using univariate and multivariate techniques.
In order to improve the diagnosis of AD we propose to
include in the analysis the information about gray matter
neurodegeneration provided by CT images. This approach takes
advantage of the majority of PET images are acquired on
scanners that allow simultaneous PET and CT data acquisition.
Specifically, we propose to calculate standardized uptake values
from 18F-FBB PET data using only voxels belonging to gray
matter in CT images. Previous works have followed similar
approaches (Villemagne et al., 2015; Rullmann et al., 2016)
but in those cases non-gray-matter voxels were discarded
only for the reference region and they were determined by
means of MRI images. The proposed approach was evaluated
using a dataset with 18F-FBB PET and CT scans from 94
subjects acquired during a longitudinal study carried out in
two hospitals from the Spanish National Health System. The
results suggest that using CT data along with 18F-FBB PET
neuroimages improves up to 7% the accuracy of separating
AD and non-AD patients, compared with using only PET
data.
2. MATERIALS AND METHODS
2.1. Participants
Ninety-four (94) subjects with cognitive impairments were
recruited in the Cognitive Behavioral Unit of two different
tertiary hospitals: the Virgen de las Nieves hospital in Granada,
Spain (72 patients) and the 9 de Octubre hospital in Valencia,
Spain (22 patients).
Patients were recruited according to the following clinical
criteria: patients with persistent or progressive unexplained
MCI Albert et al. (2011); Johnson et al. (2013), defined
according to revised Petersen criteria (Winblad et al., 2004);
patients fulfilling core clinical criteria for possible AD but an
atypical clinical course with no documented progression in the
patient’s records; patients fulfilling these core clinical criteria but
with cerebrovascular comorbidity, concomitant pharmacologic,
neurologic, or cognitive components (mixed etiology); and
those with a history of progressive dementia and atypically
early age at onset (≤ 65 years). All patients fulfilled clinical
appropriate use criteria for 18F-FBB PET scan according to
international consensus (Johnson et al., 2013). Exclusion criteria
were: the presence of a metabolic disorder (hypothyroidism,
vitamin B12 or folic acid deficiencies), psychiatric pathology
(schizophrenia or depression), MRI-diagnosed cerebrovascular
disease (infarction or hemorrhage), neurologic disease affecting
gnosis (Parkinsonian syndrome, epilepsy, etc.), pregnancy,
glycemia > 160 mg/dL, history of substance abuse, or age < 18
years.
Patients were evaluated using standardized
neuropsychological examinations that assessed the orientation,
attention, memory, executive function, language, visual and
constructive functions and behavior (Carnero Pardo, 2007). In
addition, a 18F-FBB PET and a CT scan were acquired for each
patient. The imaging protocol in both centers complied with
international guidelines (Minoshima et al., 2016). Specific details
are given in Table 1.
After at least 1 year of follow-up, experienced neurologists
established a final diagnosis for each patient on the basis of
neuropsychological examinations, the visual assessment of the
neuroimaging data and the clinical evolution of the patient. Two
subgroups were defined: (i) AD patients and (ii) healthy subjects
or patients with diseases other than AD. Table 2 shows the
group distribution and some demographic details of the patients.
Note that the second group is very heterogeneous and includes
patients with Parkinson’s disease, progressive supranuclear palsy
and psychiatry disorders among other conditions.
Each patient (or a close relative) gave written informed
consent to participate in the study and the protocol was accepted
by the Ethics Committee of the “Virgen de las Nieves” hospital
(Granada, Spain) and the “9 de Octubre” hospital (Valencia,
Spain). All the data were anonymized by the clinicians who
acquired them before being considered in this work.
2.2. Data Preprocessing
CT brain images were segmented using the unified segmentation
algorithm (Ashburner and Friston, 2005) implemented in
Statistical Parametric Mapping (SPM) version 12. This algorithm
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TABLE 1 | Protocol details to acquire neuroimaging data.
Center A Center B
Camera GE Discovery STE Siemens Biograph 16
Patient position Resting, with closed eyes Resting, with closed eyes
Operation 3D mode 3D mode
Filtering Z-Axis standard Z-Axis standard
Dose 300 MBq 300 MBq
Acq. start 90 min post injection 90 min post injection
Acq. duration 20 min 20 min
Matrix size (FBB) 168 × 168 168 × 168
Slice thichness (FBB) 4.01 mm 4.06 mm
Number of slices 70 70
Voxel size 16.08 (mm3 ) 16.48 (mm3)
Reconstruction VUE Point (5 it, 35 sub) Gaussian + OS-OM (6 it, 21
sub)
CT Parameters Low-dose, 80 mAs, 120 kV Low-dose, 50 mAs, 120 kV
Matrix size (CT) 512 × 512 512 × 512
Slice thichness (CT) 1 mm 1 mm
Corrections Scatter; CT attenuation; well
counter sensitivity and
activity; delayed event
subtraction and
normalization
Scatter; CT attenuation;
slice coincidence location
with CT
TABLE 2 | Demographic details of the patients considered in this work (µ and σ
stand for the average and the standard deviation respectively).
Sex Age
# M F µ σ range
AD 51 23 28 63.43 6.32 49–74
Non-AD 43 28 15 62.91 8.27 42–79
allows the separation of gray matter, white matter and
cerebrospinal fluid tissues from CT images. The 18F-FBB PET
images were also registered to a common space using SPM. This
proceduremade use of the deformation fields obtained during the
segmentation of the CT data in order to achieve a more accurate
transformation (Ashburner and Friston, 2007). As a result, we got
brain images in Montreal Neuroimaging Institute (MNI) space
with 121× 141× 121 voxels of 1.5× 1.5× 1.5 mm each.
2.3. Regions of Interest
Ten (10) regions of interest (ROIs) were defined to analyze
our 18F-FBB PET data: medial temporal, lateral temporal,
precuneus, posterior cingulate, anterior cingulate, frontal,
occipital, striatum, thalami, and parietal (Rodriguez-Vieitez et al.,
2016). Locations and sizes can be seen in Figure 1. These regions
are frequently associated to AD in the literature and allow
comparing our results with the ones obtained by other works
(Villemagne et al., 2012; Daerr et al., 2016; Tiepolt et al., 2016;
Tuszynski et al., 2016; Bullich et al., 2017). In order to parcel these
target regions in our brain images the Automatic Anatomical
Labeling (AAL) atlas was used (Tzourio-Mazoyer et al., 2002).
FIGURE 1 | Brain map encoding with colors the regions of interest used in this
work. They are known to be particularly useful for AD diagnosis and are widely
used in literature (Rodriguez-Vieitez et al., 2016). Axial slices at −36, −30,
−24, ..., 66 mm from the anterior commissure are shown.
2.4. Quatification of 18F-FBB PET Data
Using Structural Information
In the clinical practice, neuroimaging data are usually analyzed in
terms of standardized uptake values (SUV), which are often given
as a ratio of the uptake of a reference region (SUVR). Different
regions have been propose to be used as reference to calculate
SUVRs from amyloid PET data (Brendel et al., 2015; Klein et al.,
2015a,b; Kimura et al., 2016; Shokouhi et al., 2016). Despite there
is no general consensus, the use of the whole cerebellum (Daerr
et al., 2016; Bullich et al., 2017) or the cerebellar gray matter
(Villemagne et al., 2015) is usually accepted. The SUVR for a
given region, k, could be computed as:
SUVRk =
Nr
∑Nk
i=1 xi
Nk
∑Nr
j=1 xj
(1)
where xi is the intensity of the i-th voxel belonging to region k,
with i ∈ [1, 2...Nk] and similarly, xj stands for the intensity of the
j-th voxel belonging to a reference region, with j ∈ [1, 2...Nr]. In
this work, we used the whole cerebellum as reference region thus,
SUVRs for a given subject were weighted by the mean cerebellar
intensity of that subject. This analysis is somewhat similar to
the visual examination of the data traditionally performed by
experienced clinicians.
Instead of SUVR described by Equation 1, we propose to use
a similar measure that also takes into account structural data.
Specifically we propose to compute SUVRs using only voxels
belonging to gray matter, i.e., those whose position corresponds
to gray-matter voxels in CT data. That way we consider not only
the amyloid deposits but also the brain injury caused by the
disorder.
2.5. Fisher’s Discriminant Analysis
The Fisher’s discriminant ratio, J, (Theodoridis and
Koutroumbas, 2008) is a statistical measure widely used to
maximize the differences of means in between two or more
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FIGURE 2 | Areas with significant differences (p < 0.05, FWE) between
groups in 18F-FBB PET data. The color scale codifies the t-statistic values
(values below 4.81 are not significant).
classes respective to the within class variance (Lopez et al., 2009).
Mathematically it is defined as:
J(w) =
wTSBw
wTSWw
(2)
where w represent a direction in the data space and SB and SW
are respectively the “between classes” and the “within classes”
scatter matrices. Note that scatter matrices are proportional to
covariance matrices and, when only 2 classes are considered, SB
can be expressed as:
SB = (µ1 − µ2)(µ1 − µ2)
T (3)
where µi denotes the mean of the samples belonging to the i-th
class. This analysis was not applied to individual voxels (each
possible direction in the image space would correspond to a
specific voxel position) but to the SUVRs of the ROIs defined in
section 2.3. Thus, J was computed as:
Jr =
(
µ
(r)
1 − µ
(r)
2
)2
(
σ
(r)
1
)2
+
(
σ
(r)
2
)2 (4)
where µ(r)i and σ
(r)
i are, respectively, the mean and the standard
deviation of the SUVR of region r for subjects belonging to the
i-th class.
2.6. Support Vector Machine
A binary classification method is a statistical procedure intended
to assign a binary label (defining a category or group) to unseen
patterns represented by a set of features. To this end, supervised
TABLE 3 | AD target regions and areas with significant differences between AD
and non-AD patients in 18F-FBB PET data.
Region name Region size Area with significant diff.
Medial temporal 47171 mm 432 mm (0.92 %)
Lateral temporal 94907 mm 36732 mm (38.70 %)
Precuneus 24338 mm 9693 mm (39.83 %)
Posterior cingulate 2813 mm 551 mm (19.57 %)
Anterior cingulate 9603 mm 5346 mm (55.67 %)
Frontal 193730 mm 10424 mm (5.38 %)
Occipital 50117 mm 6248 mm (12.47 %)
Striatum 16326 mm 0 mm (0.00 %)
Thalami 7422 mm 0 mm (0.00 %)
Parietal 50763 mm 4715 mm (9.29 %)
The differences were determined by means of a t-test analysis.
methods build a function f :RD → ±1 using a set of known
patterns, xi and their labels, yi (training data):
(x1, y1), (x2, y2), ..., (xN , yN) ∈ (R
k × {±1}) (5)
Support Vector Machine (SVM) is a supervised classifier derived
from the statistical learning theory (Vapnik, 1998). In SVM the
classification function is built using a hyperplane, called maximal
margin hyperplane, that has the largest distance to the closest
training data pattern of any group:
g(x) = wTx+ w0 = 0, (6)
where w is the weight vector, orthogonal to the decision
hyperplane, and w0 is the threshold. SVM is able to work in
combination with kernel approaches when the linear separation
of the data is not possible (Müller et al., 2001). Once the
hyperplane is computed the classifier assigns a group label to each
new pattern according to the side of the hyperplane where it is.
In our experiments the cost parameter, C, was fixed to the
commonly accepted value of C = 1 and only linear kernels were
used. The evaluation of the classification performance was carried
out using a 10-fold cross-validation scheme (Varma and Simon,
2006). Given that we have data from 94 subjects, each fold uses
85 samples for training and 9 for test. In the training step of each
fold, SUVRs or voxel intensities from each training subject and a
binary label determining the group the subject belongs to (AD or
non-AD) were used as input data (variables xi and yi in Equation
5). In the test step, the classifier was used to estimate a label for
each test subject (represented by its SUVRs or voxel intensities).
The estimated labels were then compared with the real ones to
assess the classification performance.
2.7. ROC Analysis
In a classification procedure, the trade off between sensitivity
and specificity can be analyzed through a Receiver Operating
Characteristic (ROC) curve (Brown and Davis, 2006). In
these plots, each point represents a sensitivity/specificity pair
corresponding to a particular decision threshold. The upper
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FIGURE 3 | SUVR of the 10 target regions described in section 2.3. The values are grouped into 4 groups according to: (i) the class they belong to (AD or non-AD)
and (ii) how they were calculated (using all voxels (classical approach) or using only gray-matter voxels (proposed approach)). On each blue box, the central mark
indicates the median, and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively.
left corner correspond to a sensitivity and specificity of 100%,
therefore, the closer the ROC curve is to the upper left corner,
the highest accuracy. The area under the curve (AUC) allows
measuring how close is the solution to the optimal one and is
frequently used as a measure of the classification performance.
3. EXPERIMENT AND RESULTS
First, we carried out a t-test analysis on SPM to look for group
differences between AD and non-AD subjects for both, 18F-
FBB PET and CT data. As sugested in Friston et al. (2006),
a smoothed version of the brain images (Gaussian filter of 8
mm FWHM) was used. Results for PET images are shown in
Figure 2. In this case, we evaluated the hypothesis that data
from AD patients have higher intensity than those from non-AD
subjects (AD patients are expected to have a greater amyloid-
beta concentration). Voxels with significant differences (p <
0.05, FWE) between both groups are shown in a specific color
which depends on its t-statistic. In order to determine if the
colored regions match with target regions described in section
2.3, we calculated the percentage of those regions covered by
colored voxels. The results are shown in Table 3. No significant
effects were found for CT data. In this case, only the gray-
matter was used and two hypotheses were evaluated: non-AD
group has lower intensity than AD group (same as for PET
images) and AD group have lower intensity than non-AD group.
The latter hypothesis was the most plausible for CT images
since one might expect a greater neurodegeneration in AD
patients.
Afterwards, the advantages of computing SUVRs from 18F-
FBB PET data using only the gray-matter voxels were evaluated.
Figure 3 shows the median SUVR of each target region grouped
into four groups according to: i) the class they belong to (AD
or non-AD) and ii) how they were calculated: using all voxels
(classical approach) or using only gray-matter voxels (proposed
approach). The F-statistic (ANOVA) and corresponding p-value
were computed to determine whether AD and non-AD subjects
have different mean on target regions. Results using the classical
and the proposed procedure to calculate SUVRs are given in
Table 4.
The advantages of proposed SUVRs were also assessed by
means of the Fisher’s discriminant analysis. Jr values (Equation 4)
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TABLE 4 | F-statistics and corresponding p-values to determine whether AD and
non-AD patients have different mean on target regions.
Classical SUVR Proposed SUVR
Region F-statistic p-value F-statistic p-value
Medial temporal 7.9922 0.0058 6.6137 0.0117
Lateral temporal 50.3387 0.0000 53.6227 0.0000
Precuneus 27.7957 0.0000 34.3257 0.0000
Posterior cingulate 4.5438 0.0357 13.6022 0.0004
Anterior cingulate 37.1421 0.0000 41.8245 0.0000
Frontal 15.2235 0.0002 18.1024 0.0001
Occipital 17.4945 0.0001 17.9269 0.0001
Striatum 6.2384 0.0143 12.1945 0.0007
Thalami 0.0437 0.8349 0.7259 0.3964
Parietal 19.0551 0.0000 22.6125 0.0000
FIGURE 4 | Fisher’s discriminant ratio for SUVRs of target regions. Blue: Rates
for SUVRs computed using all the voxels in the region. Red: Rates for SUVRs
calculated using only gray-matter voxels. Larger values mean larger distances
between groups.
were computed to rate the usefulness of SUVRs of target regions
when separating AD and non-AD subjects. Figure 4 allows us to
compare the Jr values computed using all brain voxels with those
that considered only gray-matter voxels.
Subsequently, our data were analyzed in terms of their
usefulness to separate AD and non-AD patients using SVM
classification. Specifically, we estimated the accuracy, sensitivity
and specificity of a SVM classifier that separates the groups
using 18F-FBB PET data. Two approaches were applied: (i) using
SUVR of target regions as feature and (ii) using the intensity
of all the voxels in brain images as feature. In both cases we
compared the classification results when using or not the CT
data to exclude non-gray-matter voxels. For the approach using
all the voxels in brain images, the intensity of the voxels was
referenced to the mean uptake of the whole cerebellum. This
is similar to the intensity normalization performed during the
calculation of SUVRs but, in this case, the normalization was
individually applied to each voxel. The classification results are
shown in Table 5 and Figure 5. The trade off between sensitivity
FIGURE 5 | Intermediate accuracies obtained in the cross-validation
procedure. Blue boxes and circled dots represent accuracies’ range and
median respectively.
FIGURE 6 | ROC curves for the 4 SVM procedures implemented in this work.
and specificity of the SVM analyses was examined by means of
ROC curves. They are shown along with the AUC in Figure 6.
The weight map calculated by SVM (parameter w in Equation
6) allows us to examine the importance of each feature in
the classification procedure. SVM weights from systems using
SUVRs as feature are shown in Table 6 whereas those calculated
by systems using voxel intensities as feature are shown in
Figure 7. Note that in former systems only 10 regions were used,
thus only 10 weights were calculated. Similarly, the systems using
voxel intensities as feature computed as many weights as voxels
were used.
All the experiments were carried out on Matlab using its
statistical toolbox and specific ad hoc routines.
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4. DISCUSSION
The experiments carried out in this work corroborated that
18F-FBB PET is an useful neuroimaging modality to assist the
diagnosis of AD. Both, univariate and multivariate analyses
indicated that these data allow us to separate AD and non-AD
subjects with high accuracy. In addition, the regions commonly
focused on AD diagnosis show large group differences in 18F-FBB
TABLE 5 | Classification measures obtained by a SVM classifier when separating
AD and non-AD subjects using 18F-FBB PET data.
Data used as feature Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
SUVR (all voxels) 81.91 78.43 86.05
SUVR (gray-matter voxels) 82.98 76.47 90.70
Voxel intensity (all voxels) 81.91 80.39 83.72
Voxel intensity (gray-matter voxels) 86.17 84.31 88.37
TABLE 6 | Weight assigned to each target region by a SVM classifier that used
the SUVRs of those regions as feature.
ROI All voxels Gray-matter voxels
Medial temporal 0.09 0.17
Lateral temporal −1.90 −2.28
Precuneus −0.68 −0.88
Posterior cingulate 0.37 0.50
Anterior cingulate −0.81 −0.90
Frontal 1.10 1.45
Occipital 0.54 0.55
Striatum 0.31 0.48
Thalami 0.29 −0.16
Parietal 0.12 0.16
Two approaches to calculate SUVRs were assessed: using all the voxels in the region
(center column) and using only gray-matter voxels in the region (right column).
PET neuroimages. According to the results shown in Table 3,
lateral temporal, precuneus, posterior and anterior cingulate have
significant differences between groups. Additionally, the former
region is the more important one to separate the AD and non-
AD subjects as suggested by the results shown in Table 6. The
results shown in these tables should be carefully interpreted.
Table 3 contains the percentage of each ROI with significant
differences (p < 0.05, FWE) whereas Table 6 shows the weights
assigned by a SVM classifier to those regions when the SUVRs of
those regions were used to train the classifier. Thus, frontal is an
important region in the separation problem because the classifier
assigned it a high weight (relatively high compared with other
weights). However, only about 5.38% of voxels in this region
(according to the AAL atlas) showed significant differences in
the t-test. This suggest that the importance of frontal in the
separation problem is not homogeneous throughout the region
and some frontal “subregions” are more important than others.
It should be noted that frontal was defined as a big region
(with a volume of almost 200 cm3 in the AAL atlas), more
than 10 times larger than precuneus, a small region with high
significance but with not such a high weight. Lateral temporal
and anterior cingulate are also two important regions because
of their large absolute value in Table 6. SVM weights concern
the side of the hyperplane where patterns are placed. Thus,
negative weights are associated to regions that characterize
non-AD subjects (they “move” patterns toward the non-AD
space) whereas positive weights are associated to AD subjects
(they “move” patterns toward the AD space) (Caragea et al.,
2001). Observe that using only gray-matter voxels made the
weights more positive or more negative for all regions except
for thalami. This suggests that 18F-FBB PET data contain no
important information to separate the groups in this region.
This is consistent with t-test results, which found no significant
differences in thalami.
The t-test analysis has drawn two clear conclusions: (i) there
are significant group differences in 18F-FBB PET neuroimages
and, (ii) there are no significant group differences in CT data.
The latter conclusion can be explained by the composition of
FIGURE 7 | Weight assigned to each voxel by a SVM classifier trained using the intensity of all voxels as feature (left) and using the intensity of gray-matter voxels as
feature (right).
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the non-AD group, which contains a large proportion of subjects
with other diseases, including parkinsonian disorders, that could
have structural changes similar to AD. The lack of significant
group differences in CT datamay also be due to the neuroimaging
modality itself (Gado et al., 1983). Although a number of studies
(Grundman et al., 2002; Rathore et al., 2017) have reported
volumetric differences between AD and non-AD patients in MRI
data, the use of CT neuroimages to this purpose have been poorly
studied.
In this work we propose to use SUVRs from 18F-FBB
PET neuroimages that also considerer the gray matter
neurodegeneration in order to improve the diagnosis of
AD. In most cases, this information can be extracted from CT
data in a inexpensive and efficient way, since most of the scanners
used for PET are combined PET/CT devices. Specifically, we
propose to discard those voxels from 18F-FBB PET images not
belonging to gray matter in CT images and therefore, calculate
SUVRs using only the gray-matter voxels. The idea of discarding
non-gray-matter voxels was used in previous works (Villemagne
et al., 2015; Rullmann et al., 2016) to calculate the SUV of
the reference region or to perform intermediate corrections.
Here, we propose to apply it to the SUV calculation of all the
regions and, to this end, we propose to use CT data due to its
greater availability. This way to compute SUVs is similar to the
one used in Gonzalez-Escamilla et al. (2017) but we used CT
instead MRI images. The results obtained in this work suggest
that the proposed approach allows separating AD and non-AD
patients more accurately than using standard methods for SUVR
calculation. As shown in Figure 4, for 9 out of 10 ROIs the
computation of the SUVR that considered only the gray matter
separated the patient groups more than the SUVR computed
using standard methods. These results were corroborated
by ANOVA and SVM analyses. Tables 4, 5 show that mean
differences between groups are greater (higher F-statistics and
lower p-values) and accuracy rates in SVM classification are
larger when SUVRs were computed using only gray-matter
voxels.
SVM classification performed an accurate separation
(accuracy above 80% for the 4 studied feature sets) of the groups,
which is particularly important if we take into account that the
separation of AD patients from other neurological disorders
is more difficult than distinguishing between AD patients and
healthy subjects (as mentioned before non-AD group contains
a large number of patients with other disorders). Although the
heterogeneity of non-AD group could be seen as a limitation
of our study, this approach is, in our opinion, more interesting
because it is very similar to the clinical problem where clinicians
usually take care of non-healthy subjects and should differentiate
between AD and other disorders. The obtained accuracy rates
suggest that 18F-FBB PET data contain useful biomarkers to
develop computer-aided diagnosis systems for AD. Anyway, the
analysis of the reported accuracy rates should consider potential
labeling errors inherent in all diagnostics.
The proposed approach to calculate SUVRs must not be
confused with Partial Volume Effect correction (PVEc) methods
(Erlandsson et al., 2012; Matsubara et al., 2016; Rullmann et al.,
2016). In fact, the application of those corrections are compatible
with the way to calculate SUVRs that we are proposing. In this
work, we decided not using PVEc methods due to: (i) presently,
they are not routinely applied, neither in clinical nor in research
settings and (ii) these techniques depend on a range of model
assumptions and may result on noise amplification (Erlandsson
et al., 2012; Greve et al., 2016; Gonzalez-Escamilla et al., 2017).
5. CONCLUSIONS
In this work we have proposed to compute SUVRs from
amyloid-PET imaging considering also structural data.
Specifically, we proposed to use only gray-matter voxels,
estimated through CT images, to calculate SUVRs. In order to
evaluate the proposed approach, different experiments based
on t-test, ANOVA, FDR and SVM were carried out. A dataset
with 18F-FBB PET and CT brain images from 94 subjects
diagnosed with AD and other disorders was used for evaluation
purposes. The results of those experiments suggest that the
proposed method to calculate SUVRs allows separating AD
and non-AD subjects more accurately than SUVRs calculated
by standard methods. Additionally, the results obtained in
this work corroborated that 18F-FBB PET data are good
biomarkers to estimated brain amyloid deposits and are useful to
diagnose AD.
AUTHOR CONTRIBUTIONS
RS-V, PS-N, NT-D, AR-F, and MG-R: Data collection; FS, RS-V,
JG, JR, PS-N, and MG-R: Conception and design of the work;
FS, JG, and JR: Data analysis; FS, RS-V, JG, JR, PS-N, and MG-R:
Result interpretation; FS: Drafting the article; FS, RS-V, JG, JR,
PS-N, and MG-R: Critical revision of the article.
ACKNOWLEDGMENTS
This work was supported by the MINECO/FEDER under
the TEC2012-34306 and TEC2015-64718-R projects and the
Ministry of Economy, Innovation, Science and Employment of
the Junta de Andalucía under the Excellence Project P11-TIC-
7103. The work was also supported by the Vicerectorate of
Research and Knowledge Transfer of the University of Granada.
REFERENCES
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox,
N. C., (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s
disease: recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimers Dement. 7, 270–279. doi: 10.1016/j.jalz.2011.03.008
Alzheimer’s Association (2018). 2018 Alzheimer’s disease facts and figures.
Alzheimers Dement. 14, 367–429. doi: 10.1016/j.jalz.2018.02.001
Ashburner, J., and Friston, K. (2007). “Non-linear Registration,” in Statistical
Parametric Mapping, eds K. Friston, J. Ashburner, S. Kiebel, T. Nichols, and
W. Penny (London: Academic Press), 63–80.
Ashburner, J., and Friston, K. J. (2005). Unified segmentation. NeuroImage 26,
839–851. doi: 10.1016/j.neuroimage.2005.02.018
Frontiers in Aging Neuroscience | www.frontiersin.org 8 June 2018 | Volume 10 | Article 158
Segovia et al. Quantitative Analysis of 18F-FBB PET and CT Data
Brendel, M., Högenauer, M., Delker, A., Sauerbeck, J., Bartenstein, P., Seibyl, J.,
et al. (2015). Improved longitudinal [18F]-AV45 amyloid PET by white matter
reference and VOI-based partial volume effect correction. NeuroImage 108,
450–459. doi: 10.1016/j.neuroimage.2014.11.055
Brown, C. D., and Davis, H. T. (2006). Receiver operating characteristics curves
and related decision measures: A tutorial. Chemomet. Intell. Lab. Syst. 80,
24–38. doi: 10.1016/j.chemolab.2005.05.004
Bullich, S., Villemagne, V. L., Catafau, A. M., Jovalekic, A., Koglin, N., Rowe,
C. C., et al. (2017). Optimal reference region to measure longitudinal amyloid-
beta change with 18F-Florbetaben PET. J. Nuclear Med. 58, 1300–1306.
doi: 10.2967/jnumed.116.187351
Cabral, C., Morgado, P. M., Campos Costa, D., and Silveira, M. (2015).
Predicting conversion from MCI to AD with FDG-PET brain images
at different prodromal stages. Comput. Biol. Med. 58, 101–109.
doi: 10.1016/j.compbiomed.2015.01.003
Caragea, D., Cook, D., and Honavar, V. G. (2001). “Gaining insights into support
vector machine pattern classifiers using projection-based tour methods,”
in Proceedings of the Seventh ACM SIGKDD International Conference on
Knowledge Discovery and Data Mining, KDD ′01, (New York, NY: ACM),
251–256.
Carnero Pardo, C. (2007). Utilidad diagnóstica del Test de las Fotos (Fototest) en
el deterioro cognitivo y demencia. Neurología. 22, 860–869.
Ceccaldi, M., Jonveaux, T., Verger, A., Krolak-Salmon, P., Houzard, C., Godefroy,
O., et al. (2018). Added value of 18F-florbetaben amyloid PET in the
diagnostic workup of most complex patients with dementia in France: A
naturalistic study. Alzheimer’s Dement. 14, 293–305. doi: 10.1016/j.jalz.2017.
09.009
Daerr, S., Brendel, M., Zach, C., Mille, E., Schilling, D., Zacherl, M. J., et al. (2016).
Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine
cases. NeuroImage 14, 77–86. doi: 10.1016/j.nicl.2016.10.005
Erlandsson, K., Buvat, I., Pretorius, P. H., Thomas, B. A., and Hutton, B. F. (2012).
A review of partial volume correction techniques for emission tomography
and their applications in neurology, cardiology and oncology. Phys. Med. Biol.
57:R119. doi: 10.1088/0031-9155/57/21/R119
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., and Thompson, P. M. (2010).
The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6,
67–77. doi: 10.1038/nrneurol.2009.215
Friston, K. J., Ashburner, J. T., Kiebel, S. J., Nichols, T. E., and Penny, W. D.
(2006). Statistical Parametric Mapping: The Analysis of Functional Brain Images.
Amsterdam; Boston: Academic Press.
Gado, M., Patel, J., Hughes, C. P., Danziger, W., and Berg, L. (1983). Brain atrophy
in dementia judged by CT scan ranking. AJNR 4, 499–500.
Gonzalez-Escamilla, G., Lange, C., Teipel, S., Buchert, R., and Grothe, M. J. (2017).
PETPVE12: An SPM toolbox for Partial Volume Effects correction in brain PET
– Application to amyloid imaging with AV45-PET. NeuroImage 147, 669–677.
doi: 10.1016/j.neuroimage.2016.12.077
Greve, D. N., Salat, D. H., Bowen, S. L., Izquierdo-Garcia, D., Schultz, A. P.,
Catana, C., et al. (2016). Different partial volume correction methods lead
to different conclusions: An 18F-FDG-PET study of aging. NeuroImage 132,
334–343. doi: 10.1016/j.neuroimage.2016.02.042
Grundman, M., Sencakova, D., Jack, C. R., Petersen, R. C., Kim, H. T., Schultz,
A., et al. (2002). Brain MRI hippocampal volume and prediction of clinical
status in a mild cognitive impairment trial. J. Mol. Neurosci. 19, 23–27.
doi: 10.1007/s12031-002-0006-6
Hanyu, H., Sato, T., Hirao, K., Kanetaka, H., Iwamoto, T., and Koizumi, K. (2010).
The progression of cognitive deterioration and regional cerebral blood flow
patterns in Alzheimer’s disease: A longitudinal SPECT study. J. Neurol. Sci. 290,
96–101. doi: 10.1016/j.jns.2009.10.022
Illán, I. A., Górriz, J. M., Ramírez, J., Salas-Gonzalez, D., López, M. M., Segovia, F.,
et al. (2011). 18F-FDG PET imaging analysis for computer aided Alzheimer’s
diagnosis. Inf. Sci. 181, 903–916. doi: 10.1016/j.ins.2010.10.027
Johnson, K. A., Fox, N. C., Sperling, R. A., and Klunk, W. E. (2012). Brain
Imaging in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2:a006213.
doi: 10.1101/cshperspect.a006213
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L.,
Herscovitch, P., et al. (2013). Update on appropriate use criteria for amyloid
PET imaging: dementia experts, mild cognitive impairment, and education. J.
Nucl. Med. 54, 1011–1013. doi: 10.2967/jnumed.113.127068
Khedher, L., Ramírez, J., Górriz, J. M., Brahim, A., and Segovia, F. (2015).
Early diagnosis of Alzheimer’s disease based on partial least squares, principal
component analysis and support vector machine using segmentedMRI images.
Neurocomputing 151 (pt 1), 139–150. doi: 10.1016/j.neucom.2014.09.072
Kimura, Y., Yamada, T., Hosokawa, C., Okada, S., Nagaoka, T., and Ishii, K. (2016).
Delineation algorithm on reference region for amyloid imaging using a time
history of radioactivity. J. Nucl. Med. 57(suppl. 2), 311–311.
Klein, G., Sampat, M., Staewen, D., Scott, D., and Suhy, J. (2015a). Comparative
assessment of SUVR methods and reference regions in amyloid PET studies.
Alzheimer’s Dement. 11:P350. doi: 10.1016/j.jalz.2015.06.231
Klein, G., Sampat, M., Staewen, D., Scott, D., and Suhy, J. (2015b). Comparison
of SUVR Methods and Reference Regions in Amyloid PET. J. Nuclear Med.
56(suppl.3), 1741.
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P.,
et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh
Compound-B. Ann. Neurol. 55, 306–319. doi: 10.1002/ana.20009
Klunk, W. E., and Mathis, C. A. (2008). The future of amyloid-beta imaging: a
tale of radionuclides and tracer proliferation. Curr. Opin. Neurol. 21, 683–687.
doi: 10.1097/WCO.0b013e3283168e1a
Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun,
M., et al. (2014). Amyloid PET imaging in Alzheimer’s disease: A comparison
of three radiotracers. Eur. J. Nucl. Med. Mol. Imaging 41, 1398–1407.
doi: 10.1007/s00259-014-2753-3
Lopez, M., Ramirez, J., Gorriz, J., Salas-Gonzalez, D., Alvarez, I., Segovia,
F., et al. (2009). Automatic tool for alzheimer’s disease diagnosis using
PCA and bayesian classification rules. Electron. Lett. 45, 389–391.
doi: 10.1049/el.2009.0176
Matsubara, K., Ibaraki, M., Shimada, H., Ikoma, Y., Suhara, T., Kinoshita, T.,
et al. (2016). Impact of spillover from white matter by partial volume effect
on quantification of amyloid deposition with [11C]PiB PET. NeuroImage 143,
316–324. doi: 10.1016/j.neuroimage.2016.09.028
Minoshima, S., Drzezga, A. E., Barthel, H., Bohnen, N., Djekidel, M., Lewis,
D. H., et al. (2016). SNMMI Procedure Standard/EANM Practice Guideline
for Amyloid PET Imaging of the Brain 1.0. J. Nucl. Med. 57, 1316–1322.
doi: 10.2967/jnumed.116.174615
Müller, K., Mika, S., Rätsch, G., Tsuda, K., and Schölkopf, B. (2001). An
introduction to kernel-based learning algorithms. IEEE Trans. Neural Netw. 12,
181–201. doi: 10.1109/72.914517
Niu, H., Álvarez-Álvarez, I., Guillén-Grima, F., and Aguinaga-Ontoso, I. (2017).
Prevalence and incidence of Alzheimer’s disease in Europe: A meta-analysis.
Neurología 32, 523–532. doi: 10.1016/j.nrl.2016.02.016
Perani, D., Della Rosa, P. A., Cerami, C., Gallivanone, F., Fallanca, F., Vanoli,
E. G., et al. (2014). Validation of an optimized SPM procedure for FDG-
PET in dementia diagnosis in a clinical setting. NeuroImage 6, 445–454.
doi: 10.1016/j.nicl.2014.10.009
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., and Davatzikos, C.
(2017). A review on neuroimaging-based classification studies and associated
feature extraction methods for Alzheimer’s disease and its prodromal stages.
NeuroImage 155 (Suppl. C), 530–548. doi: 10.1016/j.neuroimage.2017.03.057
Rice, L., and Bisdas, S. (2017). The diagnostic value of FDG and amyloid
PET in Alzheimer’s disease—A systematic review. Eur. J. Radiol. 94, 16–24.
doi: 10.1016/j.ejrad.2017.07.014
Rodriguez-Vieitez, E., Carter, S. F., Chiotis, K., Saint-Aubert, L., Leuzy, A., Schöll,
M., et al. (2016). Comparison of early-phase 11C-Deuterium-l-Deprenyl and
11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer
Disease. J. Nucl. Med. 57, 1071–1077. doi: 10.2967/jnumed.115.168732
Rullmann, M., Dukart, J., Hoffmann, K.-T., Luthardt, J., Tiepolt, S., Patt, M.,
et al. (2016). Partial-volume effect correction improves quantitative analysis
of 18F-Florbetaben β-Amyloid PET Scans. J. Nucl. Med. 57, 198–203.
doi: 10.2967/jnumed.115.161893
Segovia, F., Górriz, J. M., Ramírez, J., Salas-González, D., Álvarez, I.,
López, M., et al. (2010). Classification of functional brain images
using a GMM-based multi-variate approach. Neurosci. Lett. 474, 58–62.
doi: 10.1016/j.neulet.2010.03.010
Shokouhi, S., Mckay, J. W., Baker, S. L., Kang, H., Brill, A. B., Gwirtsman, H. E.,
et al. (2016). Reference tissue normalization in longitudinal 18F-florbetapir
positron emission tomography of late mild cognitive impairment. Alzheimer’s
Res. Ther. 8:2. doi: 10.1186/s13195-016-0172-3
Frontiers in Aging Neuroscience | www.frontiersin.org 9 June 2018 | Volume 10 | Article 158
Segovia et al. Quantitative Analysis of 18F-FBB PET and CT Data
Theodoridis, S., and Koutroumbas, K. (2008). Pattern Recognition, Fourth Edition.
Amsterdam: Academic Press.
Tiepolt, S., Hesse, S., Patt, M., Luthardt, J., Schroeter, M. L., Hoffmann, K.-T.,
et al. (2016). Early 18F-florbetaben and 11C-PiB PET images are a surrogate
biomarker of neuronal injury in Alzheimer’s disease. Eur. J. Nuclear Med. Mol.
Imaging 43, 1700–1709. doi: 10.1007/s00259-016-3353-1
Tuszynski, T., Rullmann, M., Luthardt, J., Butzke, D., Tiepolt, S., Gertz, H.-
J., et al. (2016). Evaluation of software tools for automated identification
of neuroanatomical structures in quantitative β-amyloid PET imaging to
diagnose Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 43, 1077–1087.
doi: 10.1007/s00259-015-3300-6
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O.,
Delcroix, N., et al. (2002). Automated anatomical labeling of activations
in SPM using a macroscopic anatomical parcellation of the MNI
MRI single-subject brain. NeuroImage 15, 273–289. doi: 10.1006/nimg.
2001.0978
Vapnik, V. N. (1998). Statistical Learning Theory. New York, NY: Wiley-
Interscience.
Varma, S., and Simon, R. (2006). Bias in error estimation when using
cross-validation for model selection. BMC Bioinformatics 7:91.
doi: 10.1186/1471-2105-7-91
Villemagne, V. L., Bourgeat, P., Doré, V., Macaulay, L., Williams, R.,
Ames, D., et al. (2015). Amyloid imaging in therapeutic trials: The
quest for the optimal reference region. Alzheimer’s Dement. 11, P21–P22.
doi: 10.1016/j.jalz.2015.06.036
Villemagne, V. L., Mulligan, R. S., Pejoska, S., Ong, K., Jones, G., O’Keefe, G., et al.
(2012). Comparison of 11C-PiB and 18F-florbetaben for A-Beta imaging in
ageing and Alzheimer’s disease. Eur. J. Nuclear Med. Mol. Imaging 39, 983–989.
doi: 10.1007/s00259-012-2088-x
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.-
O., et al. (2004). Mild cognitive impairment – beyond controversies, towards
a consensus: report of the International Working Group on Mild Cognitive
Impairment. J. Int. Med. 256, 240–246. doi: 10.1111/j.1365-2796.2004.01380.x
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Segovia, Sánchez-Vañó, Górriz, Ramírez, Sopena-Novales, Testart
Dardel, Rodríguez-Fernández and Gómez-Río. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 10 June 2018 | Volume 10 | Article 158
